Skip to main content
Premium Trial:

Request an Annual Quote

NRGene, RCK Partner to Develop Medical Cannabis DNA Biomarkers

NEW YORK (GenomeWeb) — NRGene said today that it has partnered with Israeli cannabis production company RCK to develop DNA-based biomarkers for medical cannabis breeding and strain identification.

Under the terms of the deal, the partners will use NRGene's computational tools to develop the biomarkers for commercial use. Additional terms were not disclosed.

"Today, no reliable method exists to distinguish among cannabis strains, so the quality and purity of the produced material is uncertain," RCK Chief Technology Officer Noam Chehanovsky said in a statement. "As the plant is grown for medical treatment, and different strains are used to treat different medical conditions, it is crucial we ensure the strain's identity, [and the] quality and efficacy of every batch of the medical cannabis produced."

Earlier this year, Syngenta licensed NRGene's GenoMagic cloud-based genome analysis platform for use in crop molecular breeding and genomic selection. Ness Ziona, Israel-based NRGene also has formed agricultural partnerships for its genome assembly and analysis technologies with Illumina and Monsanto.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.